Antibody-Drug Conjugates and Immunotoxins

From Pre-Clinical Development to Therapeutic Applications

Inbunden, Engelska, 2012

Av Gail Lewis Phillips, Beverly A. Teicher

2 169 kr

Beställningsvara. Skickas inom 10-15 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

This volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.

Produktinformation

Utgivningsdatum2012-12-12
Mått155 x 235 x 26 mm
Vikt746 g
FormatInbunden
SpråkEngelska
SerieCancer Drug Discovery and Development
Antal sidor378
Upplaga2013
FörlagSpringer-Verlag New York Inc.
ISBN9781461454557

Tillhör följande kategorier

Onkologi inom Medicin
Medicinsk utrustning och medicinska tekniker inom Medicin

Antibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins.- Antibody-Drug Conjugate Development.- Components of ADC Development: Assay Methodologies and Challenges.- Clinical Pharmacology Strategies in the Development of Antibody-Drug Conjugates.- Predictive Biomarkers for Antibody-Drug Conjugates.- Factors Involved in the Design of Cytotoxic Payloads for Antibody-Drug Conjugates.- Linker Technology and Impact of Linker Design on ADC Properties.- Antibody-drug conjugates for the treatment of B-cell malignancies.- Targeting CD19 with SAR3419, an anti-CD19-Maytansinoid Conjugate for the Treatment of B Cell Malignancies.- Brentuximab Vedotin (SGN-35) for CD30 Positive Malignancies.- Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer.- CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE).- Case Study: An Antibody-Drug Conjugate Targeting MUC16 for Ovarian Cancer.- EphA2 Immunoconjugate.- Anti-PSMA Antibody-Drug Conjugates.- Targeting CD56 (NCAM)-expressing Neoplasms with Lorvotuzumab Mertansine.- Studies on the Metabolism of Antibody-Drug Conjugates.- Design, Development and Characterization of Recombinant Immunotoxins Targeting HER2/neu.- The Preclinical and Clinical Evaluation of VB6-845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors.- Index.